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All human herpesviruses (HHVs) have been implicated in immune system evasion and suppression. Moreover, two
HHV family members, i.e. EBV and KSHV, are recognised as oncogenic viruses. Our literature review summarises
additional examples of possible oncogenic mechanisms that have been attributed to other HHVs. In general, HHVs
affect almost every cancer-implicated branch of the immune system, namely tumour-promoting inflammation,
immune evasion, and immunosuppression. Some HHVs accomplish these effects by inhibiting apoptotic pathways
and by promoting proliferation. Mechanisms related to immunosupression and low grade chronic inflammation
could eventually result in the initiation and progression of cancer. In this article we open a discussion on the
members of Herpesviridae, their immune evasion and suppression mechanisms, and their possible role in cancer
development. We conclude that discerning the mechanisms of interplay between HHV, immune system, and cancer
is essential for the development of novel preventative and therapeutic approaches for cancer treatment and
prophylaxis.
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The human herpesviruses include herpes simplex viru-
ses (HSV-1 and HSV-2), varicella zoster virus (VZV),
Epstein-Barr virus (EBV), cytomegalovirus (CMV), hu-
man herpesvirus 6 and 7 (HHV-6, HHV-7) and Kaposi’s
Sarcoma-associated herpesvirus (KSHV). Herpesviruses
have acquired the unique ability to exploit a number of
immune evasion strategies. These strategies enable her-
pesviruses to persist in a latent state within host cells,
and then reactivate under certain conditions. The signifi-
cance of herpesvirus research is enhanced by accumulat-
ing data that associate these viruses with certain types of
cancer [1]. Some of the members of Herpesviridae, such
as EBV and KSHV, are officially recognized as carcino-
gens [1]. The role of CMV is well-established in brain
tumours, with evidence pointing to several oncogenic
mechanisms [2]. Other members of the Herpesviridae* Correspondence: akakpenova@nu.edu.kz
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stated.family are associated with a malignant phenotype, but
their role in carcinogenesis remains unclear and requires
further investigation. There are several direct carcino-
genic mechanisms exploited by herpesviruses, including
inhibiting apoptosis and tumour suppressor pathways,
promoting the oncogenic microenvironment, facilitating
cellular migration, metastasis, angiogenesis, and indu-
cing mutagenesis (see Table 1).
Another important topic of research is the apparent
link between herpesviruses and changes in the immune
system. Research has shown that almost every branch of
the immune system is affected by herpesvirus proteins,
microRNAs, or other products. Clinical evidence shows
that herpesviruses lead to immunosuppression and are
especially harmful in immunocompromised individuals.
There is also evidence linking herpesvirus latency with
immunosenescence [27,28]. Considering the importance
of immune surveillance in the control of cancer cell
growth, one hypothesis is that certain human herpes-
viruses can lead to cancer initiation and progressiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Direct oncogenic mechanisms exploited by human herpesviruses
Human herpesvirus Associated cancers Direct oncogenic mechanisms
Herpes simplex virus 1
and 2 (HSV-1 and HSV-2)
HSV1 was detected in benign and malignant thyroid
tumours [3], associated with prostate cancer, melanoma
incidence in both men and women [4], associated with
cervical cancer [5]
Induces unscheduled DNA synthesis [6]. In lytically infected
cells, both HSV-1 and HSV-2 possess an anti-apoptotic
activity, specifically HSV-2 protein ICP10PK, which inhibits
apoptosis through activation of Ras/Raf-1/MEK/ERK
pathway [7]
Human herpesvirus 3, or
Varicella zoster virus
Leukaemia, lymphoma, skin cancer, benign and malignant
breast tumours [8]
VZV ORF12 activates AP1, a transcription factor that
upregulates cellular proliferation [9]. VZV ORF63 inhibits
apoptosis by IE63 protein [10]
Human herpesvirus 4, or
Epstein-barr virus (EBV)
Nasopharyngeal Carcinoma, Burkitt’s Lymphoma and
Hodgkin’s lymphoma, to lesser extent
RASSF1A promoter methylation, p16 homozygous
deletions andmethylation [11,12]
HIV-positive CNS lymphomas and hypopharyngeal and
laryngeal tumours [13-15], rarely post-transplant smooth
muscle tumours [16]
Human herpesvirus 5, or
human cytomegalovirus
Glioblastoma (90% association), lymphoma, nasopharyngeal
cancer, cervical cancer, Kaposi’s sarcoma (KS), colorectal
carcinoma, prostate cancer, skin cancer, astrocytomas
[17,18]
Inducing cell cycle progression, activation cell motility
and migration, induces VEGF expression, inhibiting DNA
damage repair, inducing chromosomal aberrations,
inhibiting apoptotic pathways [2]
Human herpesviruses 6
and 7 (HHV6 and HHV7),
or roseoloviruses
Paediatric lymphoma [19]), acute lymphoblastic leukaemia
[20], basal cell carcinoma [21], glioma [22]
Restrains p53 [23], DR7 transform NIH3T3 cells [24], cell
cycle arrest at G2/M phase [25], integrate into human
chromosome [22]
Human herpesvirus 8, or
Kaposi’s sarcoma
associated virus (KSHV)
Kaposi’s sarcoma, Multicentric castleman disease (MCD),
Primary effusion lymphoma (PEL)
vIRF3 and ORF73 (LANA) inhibit p53-mediated cell cycle
arrest and apoptosis; K13 (ORF71) inhibits extrinsic
death-receptor-mediated apoptosis pathway; ORF16
encodes the viral Bcl-2 protein that inhibits apoptosis
and suppresses the cellular autophagy pathway [26]
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mechanisms. This review covers the major effects of
some human herpesviruses on different branches of
the immune system, as well as the mechanisms by
which these changes may lead to cancer.
Overview of cancer immune system evasion
The hypothesis of tumour immunosurveillance was first
proposed by Thomas and Burnet in 1957. It stated that
the human body employs its natural defences and ex-
hibits immunological resistance to the development of
cancer. This immunological response occurs during the
early stages of cancer development. The clinically detec-
table signs of tumour disease can only be seen after the
cancerous cells have already evaded the immune res-
ponse [29]. The following list of observations supports
the presence of an immune response against cancerous
cells [30,31]:
 Tumour-specific immunity, including cytotoxic
T-lymphocytes (CTLs) and antibodies.
 Favourable prognosis in immunocompetent patients.
 Cases of spontaneous regression of certain cancers.
 Strong association between immunodeficiency and
cancer.
Furthermore, tumours can escape immunosurveillance
by several mechanisms [32]: Loss or downregulation of MHC class I molecules.
 Downregulation of tumour antigens.
 Suppressing the immune response by ineffective
signals to CTLs.
 Immunosuppressive cytokine release.
The detailed discussion below will show how human
herpesviruses have been implicated in cancer initiation and
progression using immunosurveillance-based mechanisms.
Human herpesviruses 1 and 2: the herpes simplex viruses
(HSVs)
HSV-1 and HSV-2 have evolved numerous mechanisms
to evade host detection and immune responses and usu-
ally establish lifelong latency. HSV-1 has been detected
in benign and malignant thyroid tumours, while HSV-2
has been found associated with papillary thyroid cancer
and the presence of lymph node metastases [3]. Addi-
tionally, HSV-2 is associated with prostate cancer, mela-
noma incidence in both men and women [4], and cervical
cancer [5].
HSV-1 and HSV-2 impair the immune system by af-
fecting T-cell receptor signalling. These viruses inhibit
the T-cell receptor (TCR)-stimulated formation of a lin-
ker required for the activation of a T-cell signalling
complex. As a result, TCR-stimulated NF-κB activa-
tion and selective TCR-stimulated interleukin-10 synthesis
are inhibited, resulting in favoured viral replication and
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to inhibit the type I interferon response [34], and HSV-1
infected cells can resist T-cell induced apoptosis through
expression of the Us5 gene product gJ [35]. The HSV-1 in-
fected cell protein (ICP) 47 blocks the peptide transporter
(TAP), preventing access of antigenic peptides into the
class I pathway [36]. HSV-1 has also been shown to block
CTL-induced Ag-dependent apoptosis [37]. Additionally,
infection of human B lymphoblastoid cells (B-LCL) by
HSV-1 in vitro resulted in decreased ability to induce
CD4 +T cell clone proliferation and cytokine secretion
through US1 gene expression [38].
Human herpesvirus 3: varicella zoster virus (VZV)
Herpes zoster is a frequent complication of lympho-
reticular malignancy. In immunocompromised patients,
varicella may present atypically in the form of dissemi-
nated ulcerative or necrotic skin lesions [39]. Also, the
duration of replication and virus shedding can be ex-
tended, resulting in protracted disease [40]. This compli-
cation, like many others, is well-described in advanced
stages of leukaemia and lymphoproliferative disorders,
particularly after chemotherapy [41].
After initial infection, VZV establishes lifelong latency
in the sensory ganglia and reactivates upon immuno-
deficiency. Some experiments have demonstrated that
VZV preferentially infects T cells, particularly CD4 T
cells [10,42]. During initial viraemia, infected CD4 T
cells cause down regulation of the histocompatibility com-
plex class I expression and allow VZV to evade the im-
mune system [43]. In addition, infected T cells transport
VZV via T-cell trafficking from tonsillar tissue to the skin,
where VZV replicates and produces cell-free VZV, resul-
ting in highly infectious skin lesions. Uninfected T cells
also arrive at the infection sites, become primed with cell-
free VZV, and mount a systemic immune response in an
effort to control the initial infection [44]. Cellular immun-
ity clearly plays a critical role in controlling VZV reactiva-
tion, because the two main factors contributing to zoster
incidence are age (most likely reflecting immune senes-
cence) and cellular immune compromise due to disease or
iatrogenic cause. Also there is high risk of reactivation of
infection in immunocompromised patients, such as those
with leukaemia, lymphoma and other malignancies.
Although acyclovir is the standard treatment for her-
pes virus infections, resistance can develop, causing fa-
tality [45]. VZV may exacerbate the condition of cancer
patients and worsen prognosis.
Human herpesvirus 4 (Epstein-barr virus (EBV))
EBV has continued to attract considerable attention due
to its oncogenic properties and its association with a
number of human malignancies of both epithelial and
lymphoid origin [46,47]. EBV is associated with particularforms of cancers, such as Nasopharyngeal Carcinoma,
Burkitt’s lymphoma, and Hodgkin’s lymphoma. To lesser
extent, EBV can be found with HIV-positive CNS lymph-
omas, hypopharyngeal and laryngeal tumours, sinonasal
undifferentiated carcinoma, malignant melanoma, and
gastric carcinoma [13-15]. Also, the majority of post-
transplant smooth muscle tumours are associated with
EBV [16].
The initial invasion of EBV to B cells occurs via bind-
ing of viral gp350 protein to cellular receptor CD21. Pri-
mary infection of naïve B cells in the oropharynx leads
to a general infection of the circulating B cells in blood
[48]. EBV-infected B cells proliferate in response to the
latent viral proteins and RNAs [49]. To enter epithelial
cells, viral proteins BMRF-2 and gH/gL interact with cel-
lular transmembrane receptors, which initiates fusion of
the viral envelope with the epithelial cell membrane
allowing EBV invasion of the epithelial cell [50]. Glyco-
protein gp42 acts as a tropism switch and is required for
B cell infection, but inhibits epithelial cell infection [51].
Both lytic and latent infections are regulated by the
immune response. EBV has evolved different strategies
in order to evade immune system and establish latency
in memory B cells. For example, some infected B cells
deregulate latent gene expression and become long-
lived, latently infected memory B cells [27]. Other stra-
tegies include disabling immunogenic latent proteins,
expressing lytic proteins that interfere with the antigen
processing mechanism and the MHC molecule expres-
sion in infected cells, and producing viral homologs of
human cytokines [52,53].
EBV induces a strong human leukocyte antigen (HLA)
class I–restricted, antigen-specific CD8+ CTL response
in infected individuals [54]. It is believed that this re-
sponse plays an important role in regulating the virus
during both primary infection and in the long-term car-
rier state. EBV can impair CD4+ and CD8+ T-cell recog-
nition by a strong, although not complete, HLA I and
HLA II down-modulation. This effect is caused by the
activity of BNLF2a,4 BILF1 and BGLF5,1,5, which are
expressed at different time points during the lytic cycle.
Moreover, the virus actively interferes with the effector
T-cell action through the viral IL-10 homolog [52].
The transformation of EBV viral particles, such as
Epstein-Barr nuclear antigens (EBNAs), latent membrane
proteins (LMPs), and Epstein-Barr virus-encoded small
RNA (EBERs), from B cells into latently infected lym-
phoblastoid cell lines ultimately disrupts host genome
regulation. The result includes dysregulation of apop-
tosis, genetic instability, and constant proliferation [11,12].
These effects can be seen in when the virus is in both lytic
and latent cycles. In lymphoproliferative disorders ex-
pression of only EBNA 1 is revealed in type I latency [55].
Type II latency shows the expression of EBNAs and
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and LMPs are expressed mostly associated with EBV-
positive post-transplant lymphoproliferative disorders
and HIV-associated lymphoproliferative disorders [57].
EBV has been shown to specifically bind to monocytes
through a CD21-independent receptor [58]. Also, such
interactions resulted in the modulation of cytokine gene
expression, e.g., IL-1 and IL-6 production [59], and sup-
pression of the synthesis of TNF-α, a pleiotropic cy-
tokine that induces apoptosis and exhibits anticancer
activity.
Human herpesvirus 5 (human cytomegalovirus (HCMV))
HCMV has been linked to numerous cancer types, in-
cluding glioblastoma (90% association), lymphoma, na-
sopharyngeal cancer, cervical cancer, Kaposi’s sarcoma,
colorectal carcinoma, prostate cancer, skin cancer, and
astrocytomas [18]. HCMV can infect many types of im-
mune cells, including monocytes, macrophages, dendritic
cells (DCs), and granulocytes. Neutrophils are the major
carrier during an acute infection, while monocytes and
macrophages are responsible for dissemination and latent
virus reservoirs. Tumour-associated macrophages are in-
fected with HCMV within the glioblastoma [2]. HCMV-
infected monocytes fail to differentiate into DCs, thereby
inhibiting the antigen presentation process [60].
HCMV affects the immune response in a wide variety
of ways. HCMV proteins block antigen presentation and
the recognition of CTL and NK cells. A functional IL-10
homolog also inhibits the NK cell response [2]. Viral
gene products lead to CTL evasion by interfering with
TAP. Expression of antigenic peptides during latency
is linked to immune “memory inflation,” leading to im-
munosuppression and an inefficient response against new
antigens [28]. HCMV miRNA (HCMV-miR-UL112-1)
helps the host cell to evade NK cell recognition. HCMV
also induces B cell-related immune memory inflation via
immunodominant epitopes [61]. Additionally, HCMV
induces immunosuppressive M2 type macrophage re-
sponses. When residing in monocytes, HCMV blocks
cytokine-induced macrophage differentiation, leading
to impaired phagocytosis [60].
The viral transcript UL111A encodes two transcripts
that bear homology to human IL-10 (latent and active),
which function to mimic human IL-10. They inhibit
pro-inflammatory cytokine production and decrease the
expression of MHC I and II, thus exhibiting immu-
nosuppressive properties. In addition, they stimulate
proliferation and differentiation of B lymphocytes and
monocytes. This phenotype helps the virus to estab-
lish primary productive infection and contributes to
persistent viral shedding [62]. In addition, HCMV in-
duces IL-6 and TNF-α expression, contributing to onco-
genic microenvironment [2].Human herpesviruses 6 and 7 (HHV-6 and −7)
Roseoloviruses, HHV6 and HHV7, are linked to many
lymphoproliferative cancers as well as other types, in-
cluding paediatric lymphoma [19], Hodgkin’s lymph-
oma, non-Hodgkin’s lymphoma, acute leukaemia [63],
basal cell carcinoma [21] and glioma [64]. HHV6 is a
T-lymphotropic virus. HHV6 is permissive to neural,
epithelial and fibroblast cells in vitro, but has a par-
ticular tropism to immune cells, such as CD4+ T cells,
monocytes, macrophages, NK cells, and DCs. HHV6 en-
ters through human CD46 receptor, which is important
for T cell response and can induce high proliferation of
IL-10 [65]. HHV-6 is then transmitted to CD4+ T cells via
monocyte-derived DCs [66]. The virus replicates pre-
dominantly in CD4+ T lymphocytes and reduces their
proliferation [67]. HHV-6 eventually persists latently
in monocytes or macrophage-lineage cells [68]. HHV-7 in-
fects both primary CD4+ T lymphocytes and SupT1 lym-
phoblastoid T-cell line. This type of infection contributes
to cancer development due to an accumulation of cells in
gap 2/mitosis (G2/M) phase, polyploidy, and an increased
cell size. In HHV7 infected cells due to the cell-cycle regu-
lation, cdc2 is activated, thus preventing cytotoxic T-cells
activity and altering immune response [69].
HHV-6 and HHV-7 possess both immunosupressive
properties and proinflammatory properties, as indicated
by their ability to alter the cytokine expression profile of
infected cells. HHV-6A induces IL-18 and IFNγ recep-
tors, supresses the apoptotic response-associated cyto-
kines IL-6 and TNF-α, and converts T cells to a Th1
phenotype [64,65]. HHV-6A infection also promotes IL-6,
IL-8, and TGF-β production in cultures of astrocytes
[64]. Moreover, viral proteins U22, U51 and U83 resemble
human chemokines. As an example, U83 can bind to CCR
receptors expressed by leukocytes and thus promote
leukocyte infiltration [65,68]. Similarly, HHV-7 affects the
immunomodulatory cytokines mentioned above. In the
supernatants of infected cells, elevated levels of these cy-
tokines were found. On the other hand, the expression
of IL-2 was decreased and overall cytokine-induced cel-
lular proliferative responses were down-regulated by this
virus [70].
Human herpesvirus 8 (HHV-8)
The HHV-8 genome contains 86–87 open reading frames
(ORFs) or genes, about quarter of which may play a role
in modulation of host immune system. Most of these
ORFs are predicted to produce proteins that bear hom-
ology to host proteins. Thus, HHV-8 has the potential to
elaborately evade host immune response [26,71]. HHV-8
is extensively associated with two human malignancies,
KS and PEL. Additionally, the virus sequence has been de-
tected in multiple myelomas and angio-immunoblastic
lymphomas using PCR [72]. Development of HHV-8-
Alibek et al. Infectious Agents and Cancer 2014, 9:3 Page 5 of 8
http://www.infectagentscancer.com/content/9/1/3associated cancers is usually linked to immunosuppression
[10]. For example, KS occurs about 100 times more fre-
quently in untreated AIDS patients [10,73].
Since HHV-8 is transmitted mainly through saliva, it
can infect mucosal-associated macrophages, DCs, lym-
phocytes and endothelial cells. B cells are the major res-
ervoir for HHV-8 latency, where it resides as an episome
and evades host immune responses through several mo-
lecular pathways. These molecular pathways can also
directly provoke oncogenesis when host immunity is
disrupted [10,72,74].
XBP-1s protein, one of the host transcription factors
for plasma cell maturation, is also used by HHV-8 for
the transcription activation of the lytic switch protein.
Thus, HHV-8 appears to have evolved to undergo lytic
replication during the differentiation of B cells. Another
factor for B cell differentiation is cellular microRNA
(miR)-155. HHV-8 encodes its homolog, known as
miR-K12-11, which can play role in modulating pro-
cesses controlled by cellular micro-RNAs [75]. Due to
the sequence-specific regulation and non-immunogenic
properties of miRNA, arguably that viruses may apply this
strategy to improve the cellular environment for viral in-
fection and pathogenesis [76]. The viral interleukin-6
(vIL-6) protein of HHV-8 has mitogenic properties and
supports B cell proliferation [77]. It has broader cell
specificity than cellular IL-6 because it does not require
the gp-80 alpha subunit of the IL-6 receptor in order
to bind gp130 and activate IL-6 signal transduction
[26,71,78].
HHV-8 inhibits MHC class I antigen presentation
through K3 and K5 proteins, which are expressed during
lytic cycle and localized at the endoplasmic reticulum.
They contribute to increased endocytosis of MHC I mo-
lecules, followed by antigen degradation at the prote-
asome [71]. There is some evidence that HHV-8 escapes
the NK cell response by decreasing expression of NKp30,
NKp46, and CD161 receptors [73]. The HHV-8 vOX2
protein also alters cellular uptake by inhibiting the pha-
gocytosis of antibody-coated virus particles by neutro-
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HHV-8 inhibits the complement system through the
KSHVcomplement control protein (KCP) encoded in
ORF4 [26,79]. KCP is a homolog to RCA proteins that
can inactivate C3 convertases, thus preventing comple-
ment activation [71]. KCP inactivates C3 convertases by
speeding up their decomposition. Two forms of C3 con-
vertase, classical and alternative, contain C4b and C3b
components, respectively. KCP can act as a cofactor for
proteins that cleave both C4b and C3b. Thus, KCP in-
hibits complement cascade by two different mechanisms,
first by directly contributing to C3 convertase decom-
position, and second by serving as a cofactor for clea-
vage proteins of C4b and C3b [79].
Four of the HHV-8 genes encode for viral interferons
(vIRF-1 through 4), which are homologous to cellular in-
terferons. vIRFs repress the immune responses normally
mediated by cellular interferons through several mecha-
nisms. First, they prevent transcriptional activation medi-
ated by cellular Ifn. Second, they accelerate degradation of
some of the Ifn molecules. Additionally, vIRFs inhibit sig-
nalling pathways driven by type I interferons (α and β)
and Ifn-λ. Finally, these viral interferons can inhibit tran-
scription and apoptosis induced by p53 and PKR proteins
[26,71,72].
In additional to interferon homologs, the HHV-8
genome also contains chemokine homologs. Among the
HHV-8 lytic-cycle genes are three chemokines homo-
logs, vCCL-1, vCCL-2 and vCCL-3. They share about 41%
amino acid sequence similarity with CC chemokine ma-
crophage inflammatory protein (MIP)-1α [71]. These viral
chemokines reduce host antiviral response by acting as
Th2-cell receptor agonists [26].
Overview of immune system-related oncogenic
mechanisms exploited by HHVs
Human herpesviruses have developed numerous mecha-
nisms of immune evasion. Some of the effects of HHVs
on immune system may have implications in cancer initi-
ation and progression. The information presented aboveited by HHVs
oncogenic mechanism HHV(s) implicated
ntation HSV-1, HSV-2, VZV, EBV, HCMV, HHV-8
n IL-10 related HSV-1, HSV-2, EBV, HCMV, HHV-6, HHV-7, HHV-8
ell responses All HHV
HCMV, HHV-8
response KSHV
ory inflation by the
ant epitopes
EBV, HCMV
EBV, HCMV, HHV-6, HHV-7, HHV-8
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ily has unique gene products and pathways, there are
some similarities in the mechanisms by which they evade
the immune system. Table 2 summarises the two major
types of tumour-promoting mechanisms: immune sup-
pression and inflammation. It is also clear that both
innate and adaptive immune system pathways are im-
paired by the actions of HHVs. The combination of
these mechanisms may potentially initiate or reinforce
a cancer phenotype.Conclusions
Our knowledge of the role that human herpesviruses
play in cancer initiation and progression is constantly
evolving with continued investigation. Although several
direct oncogenic mechanisms have been observed, it is
clear that herpesviruses can promote tumour initiation
and/or progression using mechanisms related to the im-
mune system function and response. It is important to
note that both tumour-promoting inflammation and im-
munosuppression have been implicated in this process.
Based on the findings reviewed in this article, it is clear
that nearly all branches of the anti-tumour immune re-
sponse may be exploited by herpesviruses and their gene
products. Further studies are needed to elaborate the
role of these mechanisms in carcinogenesis and to apply
this knowledge in the development of novel cancer
therapies.
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